Exchange Traded Concepts LLC Purchases 18,196 Shares of Abbott Laboratories $ABT

Exchange Traded Concepts LLC grew its position in Abbott Laboratories (NYSE:ABT) by 31.7% in the second quarter, HoldingsChannel.com reports. The fund owned 75,528 shares of the healthcare product maker’s stock after buying an additional 18,196 shares during the period. Exchange Traded Concepts LLC’s holdings in Abbott Laboratories were worth $6,853,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. Freemont Management S.A. boosted its holdings in shares of Abbott Laboratories by 197.2% during the fourth quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock worth $1,341,000 after acquiring an additional 7,100 shares during the period. PFA Pension Forsikringsaktieselskab bought a new position in shares of Abbott Laboratories during the fourth quarter worth approximately $116,580,000. Thrivent Financial for Lutherans lifted its holdings in Abbott Laboratories by 24.3% during the 4th quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock worth $30,931,000 after purchasing an additional 48,286 shares during the last quarter. Aureus Asset Management LLC boosted its stake in Abbott Laboratories by 25.0% in the 1st quarter. Aureus Asset Management LLC now owns 331,920 shares of the healthcare product maker’s stock valued at $34,078,000 after purchasing an additional 66,422 shares during the period. Finally, Concurrent Investment Advisors LLC grew its holdings in Abbott Laboratories by 23.9% in the 4th quarter. Concurrent Investment Advisors LLC now owns 88,784 shares of the healthcare product maker’s stock valued at $11,124,000 after buying an additional 17,137 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on ABT shares. Wells Fargo & Company lifted their target price on Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. Weiss Ratings raised shares of Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, August 6th. Piper Sandler reiterated an “overweight” rating and issued a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. Wolfe Research upgraded shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 target price on the stock in a research report on Thursday, August 13th. Finally, Bank of America lowered their target price on shares of Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Three analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $118.67.

Abbott Laboratories Price Performance

Shares of ABT stock opened at $114.16 on Friday. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.49. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The business has a fifty day simple moving average of $99.51 and a 200 day simple moving average of $99.93. The company has a market cap of $197.54 billion, a P/E ratio of 36.94, a P/E/G ratio of 2.21 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The firm had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. During the same quarter in the previous year, the firm earned $1.26 earnings per share. The business’s quarterly revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, sell-side analysts forecast that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend was Wednesday, July 15th. Abbott Laboratories’s payout ratio is presently 81.55%.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott’s Instinct continuous glucose sensor is now integrated into MiniMed’s Flex automated insulin-delivery system, which is commercially shipping in the United States. The partnership expands Abbott’s presence in the growing continuous glucose-monitoring and diabetes-care markets. MiniMed Ships MiniMed Flex With Abbott’s Smallest Instinct Sensor
• Positive Sentiment: Abbott entered a multiyear agreement with HealthTab to supply Afinion 2 analyzers for point-of-care HbA1c and lipid testing in UK pharmacies, supporting the Diagnostics segment and potential NHS-linked distribution. HealthTab Enters Multi-Year Collaboration Agreement with Abbott
• Positive Sentiment: Analyst commentary continues to identify electrophysiology, continuous glucose-monitoring adoption and Abbott’s cardiovascular pipeline as important long-term growth drivers for the Medical Devices business. Abbott’s Medical Devices Growth Catalyst
• Neutral Sentiment: Recent commentary remains broadly constructive on Abbott’s long-term outlook, although one analysis characterized the stock as reasonably valued after its recent advance while another recommended a more cautious stance. This suggests valuation could limit near-term upside despite favorable operating trends.
• Negative Sentiment: Abbott agreed to pay approximately $670 million to resolve the Gill case and claims involving about 2,000 individuals concerning specialty formulas for premature infants. Although the company maintains that the products are safe and denies reliable evidence linking them to necrotizing enterocolitis, the settlement creates a substantial financial cost and keeps litigation risk in focus. Abbott Agrees to $670 Million Settlement
• Negative Sentiment: The company also settled an appeal related to a separate $495 million infant-formula verdict, reinforcing investor concerns about potential legal expenses and liabilities in the Nutrition business. Abbott Settles Appeal Over $495 Million Infant Formula Verdict

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.